Inflammatory and immune dysregulation associated lung disease

免疫或炎症调节障碍累及肺部的范围可以从原发性表现（如结节病）或相对轻微的表现（如对分枝杆菌病的孟德尔易感性免疫缺陷）。虽然这两者都可能与肺部肉芽肿性炎症有关，但临床肺部表现和治疗策略却截然不同。慢性呼吸道感染实验室（LCAI）寻求利用与临床免疫学和微生物学实验室以及NIAID和NIAMS内专注于这些疾病的其他分支机构的密切合作，描述已知和新出现的免疫和炎症性疾病的肺部表现。在过去的一年里，我们继续与北卡罗来纳大学的研究人员合作，以更好地定义STAT3在改变气道清除中的作用。我们联合获得了一项从实验室到床边的资助，该资助用于收集和分析气道上皮细胞、支气管肺泡灌洗液、痰液和其他呼吸道标本，以及表征气道清除机制和潜在缺陷的床边措施。

The pulmonary involvement in disorders of immune or inflammatory regulation can range from a primary manifestation such as with sarcoidosis or a relatively minor manifestations such as seen with the Mendelian Susceptibility to Mycobacterial Disease immune deficiencies. While both of these can be associated with granulomatous inflammation in the lung, the clinical pulmonary manifestations are quite different as are the management strategies. The Laboratory of Chronic Airway Infection (LCAI) has sought to capitalize on the close collaboration with the Laboratory of Clinical Immunology and Microbiology and other branches within the NIAID and NIAMS focused on these disorders to describe the pulmonary manifestations of known and emerging immune and inflammatory diseases. Over the past year we have continued collaboration with investigators at the University of North Carolina to better define the role of STAT3 in altered airway clearance. We were jointly awarded a Bench-to-Bedside grant that has funded collection and analysis of airway epithelial cells, bronchoalveolar lavage, sputum, and other respiratory specimen and bedside measures for characterization of the airway clearance mechanisms and potential defects.